prostate neoplasia
Download
Skip this Video
Download Presentation
PROSTATE NEOPLASIA

Loading in 2 Seconds...

play fullscreen
1 / 39

PROSTATE NEOPLASIA - PowerPoint PPT Presentation


  • 574 Views
  • Uploaded on

PROSTATE NEOPLASIA. BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER. John P. Kugler, MD, MPH COL, MC, USA. PROSTATE ANATOMY. fibromuscular tissue (30-50%) glandular epithelial cells (50-70%) peripheral zone (most cancers) central zone transition zone (BPH,low grade cancers).

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'PROSTATE NEOPLASIA' - Leo


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
prostate neoplasia

PROSTATE NEOPLASIA

BENIGN PROSTATIC HYPERPLASIA

AND

PROSTATE CANCER

John P. Kugler, MD, MPH

COL, MC, USA

prostate anatomy
PROSTATE ANATOMY
  • fibromuscular tissue (30-50%)
  • glandular epithelial cells (50-70%)
  • peripheral zone (most cancers)
  • central zone
  • transition zone (BPH,low grade cancers)
benign prostatic hyperplasia
BENIGN PROSTATIC HYPERPLASIA
  • 17% of men age 50-59 (require Rx)
  • 27% of men age 60-69 (require Rx)
  • 35% of men age 70-79 (require Rx)
  • Similar crosscultural prevalence
  • Some genetic and racial susceptibility to symptom severity (autosomal dominant)
  • Diet high in saturated fats, zinc and low in fruits and vegetables.
  • Sedentary life style.
bph proposed etiologies
BPHProposed Etiologies
  • Reawakening of the urogenital sinus to proliferate
  • Change in hormonal milieu with alterations in the testosterone/estrogen balance
  • Induction of prostatic growth factors
  • Increased stem cells/decreased stromal cell death
bph pathophysiology
BPHPathophysiology
  • Slow and insidious changes over time
  • Complex interactions between prostatic urethral resistance, intravesical pressure, detrussor functionality, neurologic integrity, and general physical health.
bph pathophysiology7
BPH Pathophysiology
  • Initial hypertrophydetrussor decompensationpoor tonediverticula formationincreasing urine volumehydronephrosisupper tract dysfunction
bph symptoms obstructive and irritative
Impairment of size/force of stream

Hesitancy

Intermittency

Terminal dribbling

Incomplete emptying

Nocturia

Frequency

Urgency

Dysuria

BPH SYMPTOMSObstructive and Irritative
other late presenting signs symptoms
Other late presenting signs/symptoms
  • Abdominal/flank pain with voiding
  • Uremiafatigue,anorexia,somnolence
  • Hernias, hemorroids, bowel habit change
  • UTI’s
  • Bladder calculi
  • Hematuria
other relevant history
Other Relevant History
  • GU History (STD, trauma, surgery)
  • Other disorders (eg. neurologic, diabetes)
  • Medications (anti-cholinergics)
  • Functional Status
bph clinical findings
BPHClinical Findings
  • Late signs of renal failure ( eg. anemia, HTN)
  • Abdominal examhydronephrosis/pyelonephritis
  • GU exam hernia, stricture, phimosis, cancer
  • DRE a smooth enlargement, “non-palpable” nodularity with a loss of distinction between the lobes. A soft/firm consistency,underestimates enlargement, can’t feel seminal vesicles
bph danger signs on dre
BPHDanger Signs on DRE
  • Firm to hard nodules
  • Irregularities, unequal lobes
  • Induration
  • Stony hard prostate
  • Any palpable nodular abnormality suggests cancer and warrants investigation
bph clinical evaluation
AUA Score to assess sx severity but NOT for DDX

DRE for prostate size, consistency,nodules, asymmetry, rectal tone and focused neuro exam

Abdominal/GU exam

UA, lytes (BUN,Creat.) PSA(interpret carefully)

Uroflowmetry/residual urine measure

Upper tract evaluation if hematuria, increased creatinine

Ultrasound

Cystoscopy

Urine cytology

BPHClinical Evaluation
bph symptoms differential diagnosis
BPH SYMPTOMSDifferential Diagnosis
  • Urethral stricture
  • Bladder neck contracture
  • Carcinoma of the prostate
  • Carcinoma of the bladder
  • Bladder calculi
  • Urinary tract infection and prostatitis
  • Neurogenic bladder
bph natural history
BPHNatural History
  • A progressive condition (usually) with histological onset in the 30’s and worse with age
  • A 50 yo has a 20-25% lifetime chance of needing a prostatectomy
  • A 40 yo who lives to 80 has a 30-40% chance of prostatectomy
  • But these numbers will change with new medical Rx and one third of patients improve on their own
  • Higher initial PSA’s predict faster growth and higher risk of acute urinary retention
bph treatment indications absolute vs relative
Severe obstruction

Urinary retention

Signs of upper tract dilatation and renal insufficiency

Moderate symptoms of prostatism

Recurrent UTI’s

Hematuria

Quality of life issues

BPH TREATMENT INDICATIONSAbsolute vs Relative
bph treatment non surgical
BPH TREATMENTNON-SURGICAL
  • Watchful waiting, AUA score < 7, 1/3 improve on own.
  • Herbal Phytotherapy (eg. Saw Palmetto)
  • Alpha-1-adrenergic antagonists (terazosin,doxazosin,tamsulosin,alfuzosin)
  • 5-Alpha-reductase inhibitors (finasteride,dutasteride)
  • Combination Rx most effective for most severe.
  • Medical Rx has likely reduced Medicare claims for BPH surgery by 50%.
bph treatment surgical
BPH TREATMENTSurgical
  • Indicated for AUA score >16
  • Transurethral Prostatectomy(TURP): 18% morbidity with .2% mortality. 80-90% improvement at 1 year but 60-75% at 5 years and 5% require repeat TURP.
  • Transurethral Incision of Prostate (TUIP): less morbidity with similar efficacy indicated for smaller prostates.
  • Open Prostatectomy: indicated for glands > 60 grams or when additional procedure needed for suprapubic/retropubic approaches
bph treatment new modalities
BPH TREATMENTNew Modalities
  • Minimally invasive: (Prostatic Stents,TUNA,TUMT, HIFU,Water-induced Thermotherapy)
  • Laser prostatectomy (VLAP,ILC,CLAP,TULIP,HoLRP)
  • Electrovaporization (TUVP,TVRP)
prostate cancer incidence prevalence
PROSTATE CANCERIncidence/Prevalence
  • Most common cancer in men. In the year 2000, 200K men were diagnosed and 30K died from the disease.
  • 21% of all cancers.
  • Increased risk with age with 30% presenting between age 70-79 and 67% between age 80-89.
  • Slowly progressive (as a rule): low gradegood prognosis, high gradepoor prognosis, and moderate gradevariable prognosis.
prostate cancer possible etiologies risk factors
PROSTATE CANCERPossible etiologies/risk factors
  • Age is the most important risk factor.
  • Genetic predisposition/ racial and family history.
  • Diet risk: high animal fat, high zinc, low vegetable and low fish(omega-3 fatty acids) intake, low selenium intake, low fruit, low vegetable intake.
  • Hormonal risk: high testosterone, high insulin, and high insulin-like growth factor.
  • Low UV light exposure, high pesticide exposure.
  • No increase in risk with BPH or vasectomy.
  • ? Protection from ASA, statins.
prostate cancer screening
PROSTATE CANCERScreening
  • DRE: can detect tumors in the posterior and lateral aspects of the gland. Can detect extension. Accuracy depends on experience of examiner.
  • PSA: must be interpreted in clinical context, higher sensitivity and lower specificity than DRE.
  • Referral for TRUS and/or sextant biopsy if DRE or PSA abnormal.
  • PPV for PSA >4 or DRE is ~30%.
  • Screening is controversial. No consensus. Morbidity and mortality data inconclusive. Informed discussion with patient is essential.
prostate cancer screening acp discussion points
Prostate Cancer Screening ACP Discussion Points
  • Prostate cancer is an important health problem.
  • The benefits of one-time or repeated screening and aggressive treatment of prostate cancer have not yet been proven.
  • DRE and PSA measurements can have both false-positive and false-negative results.
  • The probability that further invasive evaluation will be required as a result of testing is relatively high.
  • Aggressive therapy is necessary to realize any benefit from the discovery of a tumor.
prostate cancer screening acp additional discussion points
Prostate Cancer Screening ACP Additional Discussion Points
  • A small but finite risk for early death and a significant risk for chronic illness, particularly with regard to sexual and urinary function, are associated with these treatments.
  • Early detection may save lives.
  • Early detection and treatment may avert future cancer-related illness.
prostate cancer screening and treatment the key question

Prostate Cancer Screening and Treatment(the key question)

“is cure possible in those for whom it is necessary, and is cure necessary in those for whom it is possible?”

Dr. Willet Whitmore, 1990

aua 2007 annual meeting

AUA 2007 Annual Meeting

“Men are presenting at a younger age and lower stage. We are seeing fewer and fewer biochemical recurrences, and when they do occur, they are less lethal. Thousands of papers support this.”

Dr.. Anthony D’Amico,

Dana Farber Cancer Center

reasonable recommendations in 2007 for prostate screening
“Reasonable” Recommendations in 2007 for Prostate Screening
  • Yearly risk/benefit discussions for all men starting at age 50 who are expected to live 10 years. For blacks and those with + family hx start at 40-45.
  • If decision to screen: yearly DRE/PSA until co-morbidities/age (75) limit life expectancy to 10 yrs
  • Immediately refer if abnormal DRE or PSA>7.
  • Repeat PSA between 4 -7 several weeks later and refer if still >4.
  • If PSA <4, refer men who experience a PSA rise of more than .75 ng/mL/year (based on last three measurements obtained over 12 to 24 months).
the role of psa possible refinements
THE ROLE OF PSAPossible Refinements
  • Consider age and race adjustments.
  • PSA density(TRUS adjusted PSA).
  • PSA velocity (rate of change of PSA)(>.75 ng/mL/yr).
  • Free/Bound PSA values may be useful in separating elevations in PSA from BPH vs cancer.
  • Interval recommendations may change, depending on age and PSA level.
more psa refinements
More PSA Refinements
  • Delay performing test 48 hours after recent ejaculation or local trauma and wait at least 6 weeks after biopsy or TURP.
  • If PSA elevated wait 2-4 weeks and repeat to confirm. Some experts recommend antibiotics before repeat.
prostate cancer signs
PROSTATE CANCERSigns
  • Stony hard prostate.
  • Hematuria, hematospermia.
  • Irregular, firm, hard nodule on DRE.
  • Signs of obstructive uropathy/Rising AUA Score.
  • Neurologic cord compression signs.
  • Pathologic fractures/Bone pain.
  • Sudden onset of erectile dysfunction, painful ejaculation.
prostate cancer diagnosis
PROSTATE CANCERDiagnosis
  • Prostate biopsy by FNA or Biopty.
  • 33-50% chance of biopsy being malignant.
  • Differential Diagnosis: BPH, chronic prostatitis, prostatic TB, old biopsy fibrosis, prostatic cysts, prostatic calculi.
prostate cancer clinical staging
PROSTATE CANCERClinical Staging
  • DREsize, location, volume, local extension
  • TRUS/Endorectal coil MRIlocal extension
  • CT/ProstaScint Scanpre-op pelvic node assessment
  • Pelvic Lymphadenectomypelvic nodes
  • Other Tumor Markers
  • PSAhighest in transition zone tumors and well differentiated tumors. Its greatest value is in detecting recurrence
  • Bone Scanmets
prostate cancer staging tmn staging gleason scale
T1 are microscopic and non-palpable

T2 are palpable but confined to gland

T3 protrude beyond the gland capsule

T4 are fixed and extend well beyond the gland

Based on tumor histology

Grade 1 Gleason is the most well-differentiated

Grade 5 is the most poorly differentiated

Combined scores are reported (primary +secondary)(2-10)

PROSTATE CANCER STAGINGTMN Staging & Gleason Scale
prostate cancer treatment options for clinically localized disease
PROSTATE CANCERTreatment Options for Clinically Localized Disease
  • Radical prostatectomy
  • Radiation therapy (external beam or interstitial implantation)
  • Watchful Waiting
  • Possible hormonal therapy (ADT) is mostly used for locally advanced or metastatic disease. (Neoadjuvant ADT with Radiation may improve outcomes for men with intermediate/high pathological risk localized cancer.)
most important treatment issues
MOST IMPORTANT TREATMENT ISSUES
  • Patient’s medical condition/age.
  • Gleason Grade and PSA.
  • Is it Organ Confined?/Stage.
  • Estimation of outcome for individual patient.
  • Potential side effects of treatments.
  • Greatest treatment benefit-> “moderate to poor grade cancers in younger, healthier age group.”
  • Least treatment benefit-> “lower grade cancers in older, sicker age group.”
most important points for the family practitioner
MOST IMPORTANT POINTS FOR THE FAMILY PRACTITIONER
  • For BPH: It is mostly a primary care disease for both diagnosis and treatment. Know the danger signs and when to refer.
  • For Prostate Cancer: Screening and Rx may be controversial, but something is making a difference. All patients deserve an informed discussion about options.
ad